Abbott India Limited is a publicly listed Indian subsidiary of Abbott Laboratories, USA, one of the world's largest diversified healthcare companies. The company operates in a single reportable segment — Pharmaceuticals — and is a leading player in the Indian Pharmaceutical Market (IPM) with over 130+ products across six therapeutic areas.
| Metric | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2,646 | 2,939 | 3,307 | 3,679 | 4,093 | 4,310 | 4,913 | 5,349 | 5,849 | 6,409 |
| EBITDA | 415 | 455 | 641 | 718 | 872 | 1,002 | 1,165 | 1,360 | 1,701 | 1,970 |
| PAT | 255 | 277 | 401 | 450 | 593 | 691 | 799 | 949 | 1,201 | 1,414 |
| EPS (₹) | 120 | 130 | 189 | 212 | 279 | 325 | 376 | 447 | 565 | 666 |
| DPS (₹) | 35 | 40 | 50 | 65 | 65 | 250 | 275 | 325 | 410 | 475 |
| Employees | 2,956 | 3,083 | 3,322 | 3,485 | 3,551 | 3,585 | 3,597 | 3,700 | 3,814 | 3,659 |
DPS for FY19-FY23 includes special dividends. FY21: ₹107+₹143sp; FY22: ₹120+₹155sp; FY23: ₹180+₹145sp.
| Particulars (₹ Cr) | Q3 FY26 | Q3 FY25 | YoY % | 9M FY26 | 9M FY25 | YoY % |
|---|---|---|---|---|---|---|
| Revenue from Operations | 1,724.06 | 1,559.62 | +10.6% | 5,219.54 | 4,701.23 | +11.0% |
| Total Expenses | 1,225.51 | 1,126.09 | +8.8% | 3,696.13 | 3,371.25 | +9.6% |
| Profit Before Tax | 505.02 | 440.20 | +14.7% | 1,548.06 | 1,352.76 | +14.4% |
| Profit After Tax | 375.96 | 328.24 | +14.5% | 1,157.09 | 1,010.20 | +14.5% |
| Basic EPS (₹) | 176.92 | 154.45 | +14.6% | 544.51 | 475.38 | +14.5% |
Unaudited results. Board approved on February 12, 2026. Auditor: Walker Chandiok & Co LLP.
| Metric | FY22 | FY23 | FY24 | FY25 | Trend |
|---|---|---|---|---|---|
| EBITDA Margin (%) | 23.7% | 25.4% | 29.1% | 30.7% | ▲ Expanding |
| PAT Margin (%) | 16.3% | 17.7% | 20.5% | 22.1% | ▲ Expanding |
| RoCE (%) | 29.5% | 31.6% | 34.9% | 35.7% | ▲ Improving |
| Return on Equity (%) | — | — | 34.88% | 35.66% | ▲ Improving |
| Net Profit Ratio (%) | — | — | 20.54% | 22.07% | ▲ +153 bps |
| Current Ratio | — | — | 2.42 | 3.37 | ▲ Improved |
Abbott India operates across 6 major therapeutic areas, each with market-leading brands and a strong pipeline of new launches from its parent company.
Largest therapeutic area. Dominant franchise across acid reflux, liver disorders, GI motility, pancreatic insufficiency, and constipation.
Focused on menstrual health, pregnancy support, menopause management, and hormonal therapies.
Thyroid health, Vitamin D supplementation, and metabolic disorder management.
Vertigo management, sleep disorders, neuropathic pain, and psychiatric conditions.
Influenza and pneumococcal vaccine franchise, primarily in-licensed from the parent network.
Pain management, UTI care, vitamins, and general healthcare products spanning multiple therapeutic areas.
| Year | Brands in Top 100 | Brands in Top 300 | Brands #1 in RPM |
|---|---|---|---|
| FY22 | 5 | — | — |
| FY23 | 6 | — | — |
| FY24 | 7 | 11 | 12 |
| FY25 | 8 | 10 | 16 |
| Brand | Therapeutic Area | Indication |
|---|---|---|
| Thyronorm | Metabolics | Hypothyroidism |
| Udiliv | GI | Liver disorders (UDCA) |
| Duphaston | Women's Health | Progesterone support |
| Duphalac | GI | Constipation (Lactulose) |
| Digene | GI | Antacid |
| Cremaffin Plus | GI | Constipation |
| Vertin | CNS | Vertigo |
| Brufen | Multi | Pain / NSAID |
| Creon | GI | Pancreatic insufficiency |
| Influvac | Vaccines | Influenza vaccine |
| Zolfresh | CNS | Sleep disorders |
| Arachitol | Metabolics | Vitamin D |
| Ganaton | GI | GI motility |
| Heptral | GI | Liver health |
Abbott India consistently leverages its parent company's global R&D pipeline, launching 7–10 new products annually across its therapeutic areas. Many products are in-licensed from Abbott Laboratories' global portfolio or partner companies.
Key highlights: Pneumoshield 14 (14-valent pneumococcal vaccine) — major in-license from parent's vaccine network. Vonefi — PCAB class entry in GI. Duphaston OD — once-daily reformulation for Women's Health compliance improvement.
Key highlights: Arachitol Gummies — extending Vitamin D franchise to gummy format. Solfe FCM — IV iron injection for iron deficiency anemia. Zolfresh ER/ODT — line extensions for sleep franchise.
Continued portfolio expansion across therapeutic areas.
Revenue growth of 14.0% — highest in the FY22-FY25 period — partly driven by new launches and base recovery post-COVID.
Abbott India benefits significantly from its parent's global R&D pipeline. Key in-licensed products include Creon (pancreatic enzyme), Influvac (influenza vaccine), Pneumoshield (pneumococcal vaccine), Heptral (liver health), and Duphaston (progesterone). The company purchases raw materials and finished goods from Abbott Products Operations AG, Switzerland (₹533 Cr in FY25) and Abbott Healthcare Private Ltd., India (₹55 Cr in FY25), with access to marketing rights of the parent's affiliates for which no price is paid or payable.
| Transaction | Counterparty | FY25 | FY24 | Change |
|---|---|---|---|---|
| Payments to Ultimate Holding Company | ||||
| Payment towards RSU (Note 16) | Abbott Laboratories, USA | 15.85 | 14.36 | +10.4% |
| ESPP reimbursement | Abbott Laboratories, USA | 3.98 | 2.95 | +34.9% |
| Receivable from parent | Abbott Laboratories, USA | 5.35 | 5.04 | +6.2% |
| Purchases from Fellow Subsidiaries | ||||
| Raw materials | Abbott Products Operations AG, Switzerland | 412.79 | 270.20 | +52.8% |
| Stock-in-trade | Abbott Products Operations AG, Switzerland | 120.52 | 103.57 | +16.4% |
| Stock-in-trade | Abbott Healthcare Pvt Ltd, India | 54.52 | 67.88 | -19.7% |
| Raw materials | Abbott Healthcare Pvt Ltd, India | 0.24 | 5.74 | -95.8% |
| Total RPT Purchases | 588.07 | 447.39 | +31.4% | |
| Expenses to Fellow Subsidiaries | ||||
| Shared & support services | Abbott Healthcare Pvt Ltd, India | 51.98 | 54.15 | -4.0% |
| Conversion charges | Abbott Healthcare Pvt Ltd, India | 63.12 | 54.65 | +15.5% |
| Lease payments | Abbott Healthcare Pvt Ltd, India | 34.18 | 33.21 | +2.9% |
| Dividend Payments to Promoters | ||||
| Dividend | Abbott Capital India Ltd., UK (50.45%) | 439.48 | 348.37 | +26.2% |
| Dividend | Abbott Healthcare Products Ltd., UK (17.62%) | 153.54 | 121.71 | +26.1% |
| Dividend | British Colloids Ltd., UK (6.92%) | 60.27 | 47.78 | +26.1% |
| Total Dividend to Promoters | 653.29 | 517.86 | +26.1% | |
| Outstanding Balances | ||||
| Trade payables to related parties | All entities | 170.34 | 90.17 | +88.9% |
| Lease liabilities | Abbott Healthcare Pvt Ltd, India | 149.75 | 29.84 | +401.7% |
| Trade receivables from related parties | All entities | 18.13 | 18.64 | -2.7% |
Related party purchases as a % of total purchases were 14.02% in FY24 (down from 17.08% in FY23). The FY25 figure rose significantly with Switzerland purchases jumping 52.8%, likely reflecting new product in-licensing (Pneumoshield 14, Vonefi) and inventory build-up. Trade payables to Switzerland (₹154.58 Cr) nearly doubled, confirming increased procurement from the parent network.
FY19: ₹50+₹15sp | FY20: ₹50+₹15sp | FY21: ₹107+₹143sp | FY22: ₹120+₹155sp | FY23: ₹180+₹145sp | FY24 & FY25: Final dividend only. FY25 proposed ₹475/share pending AGM approval (Aug 13, 2025).
| Ratio | FY25 | FY24 | Change |
|---|---|---|---|
| Current Ratio (times) | 3.37 | 2.42 | +39.3% |
| Debt-Equity Ratio (times) | 0.05 | 0.02 | +150%* |
| Debt Service Coverage Ratio | 23.19 | 19.87 | +16.7% |
| Return on Equity (%) | 35.66% | 34.88% | +78 bps |
| Inventory Turnover (times) | 4.66 | 5.08 | -8.3% |
| Trade Receivable Turnover (times) | 18.33 | 18.34 | Flat |
| Trade Payable Turnover (times) | 4.26 | 4.00 | +6.5% |
| Net Capital Turnover (times) | 1.92 | 3.07 | -37.5%** |
| Net Profit Ratio (%) | 22.07% | 20.54% | +153 bps |
| Return on Capital Employed (%) | 42.86% | 43.10% | -24 bps |
| Return on Investment (%) | 7.11% | 6.83% | +28 bps |
* Debt increase due to lease renewal. ** Working capital turnover change due to deposits maturing within 12 months.
| Balance Sheet Item (₹ Cr) | FY25 | FY24 | Change |
|---|---|---|---|
| Total Equity | 4,233.15 | 3,690.93 | +14.7% |
| Non-Current Liabilities | 267.41 | 131.83 | +102.8% |
| Current Liabilities | 1,416.75 | 1,447.98 | -2.2% |
| Total Assets | 5,917.31 | 5,270.74 | +12.3% |
| Cash & Equivalents | 560.59 | 291.74 | +92.2% |
| Bank Deposits (>3m) | 1,067.33 | 1,842.75 | -42.1% |
| Fixed Deposits (>12m) | 672.00 | 1,506.00 | -55.4% |
| Cash from Operations (net of tax) | 1,011.84 | — | — |
Non-current liability increase driven by new lease agreements (₹149.75 Cr with Abbott Healthcare Pvt Ltd). The company is virtually debt-free (only lease liabilities). Deposit movements reflect maturity and reinvestment cycles.